Posted by Michael Wonder on 09 Apr 2022
PBAC recommendation for nirmatrelvir and ritonavir (Paxlovid) - March 2022
9 April 2022 - The PBAC undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and ritonavir (Paxlovid) to the PBS for use in treating patients with mild to moderate COVID-19 who are at risk of developing severe disease requiring hospitalisation.
The expedited consideration by PBAC recognises the urgent public health need related to the prevention, management, or treatment of SARS-CoV-2 infections.
